Generic Tamoxifen

Buy Generic Tamoxifen () without prescription in Canada

In our Canadian pharmacy, you can buy Tamoxifen without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Tamoxifen citrate is a selective estrogen receptor modulator (SERM) with anti‑estrogenic activity in breast tissue and estrogen‑like effects on bone, endometrium, and serum lipids. It is used primarily for the treatment of estrogen receptor‑positive breast cancer in pre‑ and postmenopausal women, and for the reduction of breast cancer risk in women at high risk. Tamoxifen works by competing with endogenous estrogen for binding to the estrogen receptor in tumour cells, thereby inhibiting estrogen‑stimulated growth. Additionally, it can stimulate ovulation and is used off‑label for infertility treatment.

Usual adult dose: For adjuvant treatment of early breast cancer and for metastatic disease, the recommended dose is 20 mg taken orally once daily (or 10 mg twice daily). For breast cancer risk reduction in high‑risk women, the dose is 20 mg once daily for 5 years. For ovulation induction (off‑label), 5–40 mg twice daily is given for 4 days starting on day 2 of the menstrual cycle, with dose escalation in subsequent cycles if ovulation does not occur. The 10 mg tablet may be used when lower doses are required or to allow divided daily dosing. Doses above 20 mg/day are generally not more effective in breast cancer and are associated with greater toxicity.

Dosage form: Oral tablets: 10 mg and 20 mg of tamoxifen (as tamoxifen citrate).

Onset of action: In breast cancer, objective tumour responses may be observed within weeks to months. The full therapeutic effect requires several months of continuous daily therapy. In risk reduction, the protective benefit is observed after 5 years of treatment and persists for at least another 5 years after discontinuation. For ovulation induction, ovulation typically occurs 5–10 days after the last dose of a treatment cycle.

Duration of action: The elimination half‑life of tamoxifen is approximately 5–7 days; its major active metabolite, endoxifen, has a half‑life of about 14 days. Steady‑state concentrations are achieved after 3–4 weeks of daily dosing. The anti‑estrogenic effect persists for weeks after discontinuation, and the risk‑reducing effect for breast cancer persists for at least 5 years after completing the 5‑year treatment course.

Alcohol recommendation: Alcohol consumption should be limited during treatment with Tamoxifen. Heavy alcohol intake may increase the risk of liver toxicity and can contribute to estrogen‑related side effects. Moderate alcohol consumption is generally considered acceptable, but patients should discuss their individual risk with their oncologist.

Most common side effects: Hot flushes (up to 80%), vaginal discharge or bleeding, menstrual irregularities, fluid retention, fatigue, nausea, and skin rash. Women may also experience mood disturbances and decreased libido. The most serious adverse effects include endometrial cancer (2‑ to 4‑fold increased risk), uterine sarcoma, venous thromboembolism (deep vein thrombosis, pulmonary embolism), and, in rare cases, ocular toxicity (cataracts, retinopathy). The risk of these serious events is higher with prolonged therapy (beyond 5 years) and in older women. Tamoxifen is also associated with a small increase in the risk of stroke.

Would you like to try Tamoxifen without a prescription?

General Information about Tamoxifen

• INN (International Nonproprietary Name): Tamoxifen (as tamoxifen citrate).
• Brand names available in Canada: The original brand name Nolvadex® (AstraZeneca Canada Inc.) is no longer marketed. Generic versions are widely available and include APO‑Tamoxifen (Apotex Inc.), TEVA‑Tamoxifen (Teva Canada Limited), Sandoz Tamoxifen (Sandoz Canada Inc.), PMS‑Tamoxifen (Pharmascience Inc.), and others. Tamoxifen is also available as a 10 mg and 20 mg tablet from several other manufacturers.
• ATC code: L02BA01 (hormone antagonists and related agents, anti‑estrogens).
• Dosage forms and strengths: Oral tablets: 10 mg and 20 mg (as tamoxifen citrate). The 10 mg tablet is typically round, white, and scored; the 20 mg tablet is round, white, and may or may not be scored depending on the manufacturer.
• Manufacturers in Canada: Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., AA Pharma Inc., and other generic pharmaceutical companies. Historically, AstraZeneca Canada Inc. manufactured Nolvadex.
• Registration status in Canada: Approved by Health Canada. First marketed in Canada in the 1970s. Multiple generic formulations are currently marketed and available by prescription. DINs: 02063516 (APO‑Tamoxifen 10 mg), 02063524 (APO‑Tamoxifen 20 mg), among many others.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. A valid prescription from a licensed Canadian healthcare professional is required.

Mechanism of Action and Pharmacology

Tamoxifen is a non‑steroidal triphenylethylene derivative that acts as a selective estrogen receptor modulator (SERM). Its biological effects are tissue‑specific and are mediated primarily through its active metabolite, endoxifen (4‑hydroxy‑N‑desmethyl‑tamoxifen), which is formed by the cytochrome P450 enzyme CYP2D6. In breast tissue, tamoxifen and its metabolites bind to estrogen receptors (ER‑α and ER‑β) and act as competitive antagonists, blocking the proliferative effects of endogenous estrogen on breast epithelial cells. This anti‑estrogenic action inhibits the growth of estrogen receptor‑positive (ER+) breast tumours. In other tissues, tamoxifen exerts estrogen‑like agonist effects: in bone, it helps preserve bone mineral density in postmenopausal women; in the endometrium, it stimulates proliferation, which accounts for the increased risk of endometrial hyperplasia and carcinoma; in the liver, it reduces serum cholesterol and alters the synthesis of coagulation factors, which may partly explain the increased risk of thromboembolic events. Tamoxifen also has central nervous system effects, affecting thermoregulation (resulting in hot flushes) and gonadotropin secretion. In premenopausal women, the anti‑estrogenic effect on the hypothalamus leads to an increase in gonadotropin‑releasing hormone (GnRH) and subsequent elevation of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH), which can stimulate ovulation—the basis for its off‑label use in infertility.

Tamoxifen is well absorbed after oral administration, with peak plasma concentrations of the parent drug occurring approximately 5 hours after a dose. It undergoes extensive hepatic metabolism, primarily by CYP2D6 and CYP3A4, to several metabolites, the most important of which is endoxifen, which has a 100‑fold greater affinity for the estrogen receptor than tamoxifen itself. The elimination half‑life of tamoxifen is 5–7 days; the half‑life of endoxifen is approximately 14 days. Steady‑state plasma concentrations of both parent drug and endoxifen are achieved after 3–4 weeks of daily dosing. Excretion occurs primarily via the faeces, with a small fraction eliminated in the urine. Because of its long half‑life, tamoxifen should be discontinued at least 2–3 weeks before major elective surgery to allow drug levels to decline and reduce thromboembolic risk.

Indications

• Breast Cancer Treatment: Tamoxifen is indicated for the treatment of estrogen receptor‑positive (ER+) breast cancer in women of all ages. This includes: adjuvant therapy of early‑stage breast cancer following surgery and radiation, treatment of metastatic breast cancer, and treatment of ductal carcinoma in situ (DCIS) following breast‑conserving surgery and radiation to reduce the risk of invasive breast cancer.
• Breast Cancer Risk Reduction: Tamoxifen is indicated for the reduction of the incidence of invasive breast cancer in women at high risk, including those with a strong family history, a personal history of atypical hyperplasia or lobular carcinoma in situ (LCIS), or a Gail model risk score of ≥ 1.66%. The recommended duration of risk‑reducing therapy is 5 years, after which the protective effect persists for at least another 5 years.
• Off‑label Use for Infertility: Tamoxifen is used off‑label for ovulation induction in anovulatory women, particularly those with polycystic ovary syndrome (PCOS) who are clomiphene‑resistant. It is administered in a 5‑day regimen starting on day 2 of the menstrual cycle.
• Tamoxifen is not indicated for use in men with breast cancer, although it is used off‑label for this purpose. It is not indicated for hormone‑receptor‑negative breast cancer.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Tamoxifen is absolutely contraindicated during pregnancy. It can cause fetal harm, including spontaneous abortion, birth defects, and fetal death when administered to a pregnant woman. Women of childbearing potential must have a negative pregnancy test before starting tamoxifen and must use effective non‑hormonal contraception during therapy and for at least 2 months after the last dose. If pregnancy occurs, the drug must be discontinued immediately.
• Breastfeeding: It is not known whether tamoxifen is excreted in human breast milk. Because of the potential for serious adverse reactions in a nursing infant, including inhibition of lactation, breastfeeding is contraindicated during tamoxifen therapy. A decision must be made whether to discontinue breastfeeding or to discontinue the drug.
• Paediatrics (< 18 years): The safety and efficacy of tamoxifen in children have not been established. It is not indicated for paediatric use, except in rare cases of McCune‑Albright syndrome under specialist guidance.
• Elderly: No dose adjustment is required based on age alone. However, elderly women, particularly those over 70 years, are at higher absolute risk of endometrial cancer, thromboembolic events, and stroke while taking tamoxifen. The risks and benefits should be carefully weighed.
• Endometrial cancer and uterine sarcoma: Tamoxifen significantly increases the risk of endometrial carcinoma (approximately 2‑ to 4‑fold over 5 years) and has been associated with an increased risk of uterine sarcoma, including malignant mixed Müllerian tumours. All women with an intact uterus should undergo annual gynaecological examinations, and any abnormal vaginal bleeding, spotting, or pelvic pain must be promptly investigated with endometrial biopsy. Routine screening endometrial biopsy in asymptomatic women is not recommended.
• Venous thromboembolism (VTE): Tamoxifen increases the risk of deep vein thrombosis, pulmonary embolism, and superficial thrombophlebitis. The risk is higher in older women, those with a personal or family history of VTE, severe obesity, or prolonged immobilisation. Tamoxifen should be discontinued at least 2–3 weeks before major elective surgery and during prolonged immobility, and should not be restarted until the patient is fully mobile.
• Stroke: Tamoxifen is associated with a small but statistically significant increase in the risk of ischaemic stroke, particularly in women over 50 years of age. Careful assessment of cardiovascular risk factors is necessary before initiating therapy.
• Ocular toxicity: Tamoxifen has been associated with retinopathy, corneal opacities, cataracts, and optic neuritis. All patients should have a baseline ophthalmologic examination and be monitored periodically for visual symptoms. Any unexplained visual disturbances should be promptly evaluated, and tamoxifen should be discontinued if retinopathy is confirmed.
• Hepatic impairment: Tamoxifen is extensively metabolised by the liver. Use with caution in patients with hepatic impairment, as drug accumulation may occur. Liver function tests should be monitored periodically during therapy.
• Bone mineral density: In premenopausal women, tamoxifen may cause a slight decrease in bone mineral density. In postmenopausal women, tamoxifen has a weak estrogen‑agonist effect on bone and may help preserve bone density. Osteoporosis risk should be assessed and managed appropriately.
• CYP2D6 polymorphism: Endoxifen, the most active metabolite of tamoxifen, is formed primarily by CYP2D6. Women with reduced or absent CYP2D6 activity (poor metabolisers) have significantly lower endoxifen levels, which may reduce tamoxifen efficacy. Concomitant use of strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, bupropion) should be avoided when possible, as these agents similarly reduce endoxifen formation and may compromise therapeutic effect.
• Allergy: Do not take Tamoxifen if you have a known hypersensitivity to tamoxifen citrate or any excipient in the formulation.

Driving and alcohol

Tamoxifen is not known to significantly impair the ability to drive or operate machinery. However, some patients may experience fatigue, dizziness, or visual disturbances. Patients should ensure they are not adversely affected before driving. Alcohol consumption should be limited during treatment. Chronic heavy alcohol use can place additional strain on the liver and may increase the risk of hepatic complications. Moderate alcohol intake (no more than one drink per day) is generally acceptable, but the oncologist should be consulted.

Dosage Instructions

• Breast cancer treatment (adjuvant and metastatic): The recommended dose is 20 mg taken orally once daily, or 10 mg twice daily. Therapy is typically continued for 5 years for adjuvant treatment; extending to 10 years may be considered in some high‑risk patients after discussion of risks and benefits. For metastatic disease, therapy continues as long as a clinical benefit is observed.
• Breast cancer risk reduction: The recommended dose is 20 mg taken orally once daily for 5 years.
• Ovulation induction (off‑label): The usual starting dose is 10–20 mg twice daily (or 5–40 mg/day in divided doses) on days 2 through 5 of the menstrual cycle. If ovulation does not occur, the dose may be increased in subsequent cycles under specialist supervision.
• Administration: The tablet(s) should be swallowed whole with a glass of water, with or without food. A consistent daily routine (e.g., taking the tablet at the same time each morning) is recommended. Do not crush, chew, or split the tablets unless the tablet is scored and a half‑dose is prescribed.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and resume the regular daily schedule. Do not double the dose.
• Discontinuation for surgery: Tamoxifen should be discontinued at least 2–3 weeks before major elective surgery and restarted only after the patient is fully ambulatory, to reduce the risk of thromboembolism.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Hot flushes (up to 80%), vaginal discharge, menstrual irregularities (in premenopausal women), fluid retention, fatigue, nausea, and skin rash.
• Common side effects (1‑10%): Vaginal bleeding, depression, decreased libido, headache, dizziness, leg cramps, and alopecia (hair thinning).
• Serious adverse reactions: Endometrial carcinoma (2‑ to 4‑fold relative risk), uterine sarcoma (rare but increased), venous thromboembolism (deep vein thrombosis, pulmonary embolism, superficial thrombophlebitis), ischaemic stroke, ocular toxicity (cataracts, retinopathy, optic neuritis), hepatotoxicity (elevated liver enzymes, steatohepatitis, rare cases of hepatocellular carcinoma), and hypercalcaemia in patients with bone metastases (usually early in treatment).
• Post‑marketing reports: Severe cutaneous adverse reactions including Stevens‑Johnson syndrome and erythema multiforme have been reported very rarely. Cases of pancreatitis and interstitial pneumonitis have also been observed.
• Contraindications: Known hypersensitivity to tamoxifen citrate or any excipient. Pregnancy and breastfeeding. Concomitant use with anastrozole or letrozole (aromatase inhibitors) in postmenopausal women when tamoxifen is not the primary endocrine therapy; the combination does not improve outcomes and may increase toxicity. Use in children is not indicated. Active venous thromboembolism or a recent history of thromboembolic events requires careful risk‑benefit assessment.

Drug Interactions

• Strong CYP2D6 inhibitors — avoid concomitant use: Paroxetine, fluoxetine, bupropion, quinidine, terbinafine, and other strong CYP2D6 inhibitors can significantly reduce the formation of endoxifen, potentially decreasing tamoxifen efficacy. If antidepressant therapy is required, citalopram, escitalopram, venlafaxine, desvenlafaxine, or mirtazapine are preferred because they have minimal CYP2D6 inhibitory activity.
• CYP3A4 inducers — potential reduced efficacy: Rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John’s wort may increase tamoxifen metabolism and reduce endoxifen concentrations. Concomitant use should be avoided when possible.
• Warfarin and other coumarin anticoagulants — major interaction: Tamoxifen potentiates the anticoagulant effect of warfarin and can lead to clinically significant increases in the International Normalised Ratio (INR) and bleeding risk. Close monitoring of INR and dose adjustment of warfarin are required; this combination should generally be avoided. If concurrent use is unavoidable, reduced warfarin doses and frequent INR monitoring are essential.
• Hormonal contraceptives — avoid: Estrogen‑ and progestin‑containing contraceptives may interfere with tamoxifen therapy and increase the risk of thromboembolic events. Non‑hormonal methods of contraception (e.g., copper intrauterine device, barrier methods) should be used.
• Aromatase inhibitors (anastrozole, letrozole, exemestane): The combination of tamoxifen with an aromatase inhibitor does not provide additional clinical benefit over sequential therapy and may increase toxicity; it is not recommended.
• Other highly protein‑bound drugs: Tamoxifen is highly bound to plasma proteins (greater than 99%). However, no clinically significant displacement interactions have been demonstrated with other protein‑bound drugs.

Practical Advice

• Administration: Take Tamoxifen exactly as prescribed, once daily (or twice daily if using 10 mg twice daily). Swallow the tablet(s) whole with a glass of water, with or without food. Adherence is essential for achieving optimal breast cancer outcomes; use a pill organiser or set a daily reminder if needed.
• Monitoring: All women should have a baseline gynaecological examination and annual follow‑up examinations while on tamoxifen. Any abnormal vaginal bleeding, spotting, or pelvic pain should be reported immediately and investigated. An ophthalmologic examination is recommended at baseline and should be repeated if visual symptoms develop. Liver function tests should be checked periodically. Bone mineral density may be monitored in postmenopausal women as appropriate. In premenopausal women using tamoxifen for ovulation induction, pelvic ultrasound monitoring and assessment of ovulation are performed by the fertility specialist.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed. Keep out of the reach and sight of children.
• Lifestyle: While on tamoxifen, avoid prolonged immobilisation; when travelling, move legs periodically and consider compression stockings to reduce the risk of blood clots. If you are scheduled for surgery or anticipate prolonged bed rest, inform your doctor so that tamoxifen can be temporarily discontinued. Limit alcohol, and avoid smoking, which compounds cardiovascular risk. Use non‑hormonal methods of contraception; do not become pregnant while taking tamoxifen. Maintain a healthy diet, exercise regularly, and ensure adequate calcium and vitamin D intake to support bone health.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not take a double dose.
• When to seek medical review: Contact your doctor immediately if you experience: abnormal vaginal bleeding or spotting; pelvic pain or pressure; leg swelling, pain, or redness; sudden chest pain or shortness of breath; sudden severe headache, confusion, or weakness on one side of the body; new visual disturbances; or jaundice (yellowing of the skin or eyes). Seek emergency care for any signs of a blood clot or stroke.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Aromatase inhibitors (AIs): Anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®) are first‑line endocrine therapies for postmenopausal women with ER+ breast cancer, and are superior to tamoxifen in reducing the risk of recurrence. They work by inhibiting the peripheral conversion of androgens to estrogens. AIs do not increase the risk of endometrial cancer and have a lower risk of thromboembolic events but are associated with more profound bone loss, arthralgia, and musculoskeletal symptoms.
• Selective estrogen receptor degraders (SERDs): Fulvestrant (Faslodex®) is an injectable SERD that binds to the estrogen receptor and accelerates its degradation. It is used for advanced breast cancer after progression on tamoxifen or an AI.
• Ovarian suppression: In premenopausal women, ovarian suppression (by gonadotropin‑releasing hormone [GnRH] agonists such as goserelin [Zoladex®] or leuprolide [Lupron®]) combined with tamoxifen or an AI may further reduce the risk of recurrence in high‑risk patients.
• Raloxifene (Evista®): Another SERM approved in Canada for the prevention of osteoporosis and reduction of invasive breast cancer risk in postmenopausal women. Raloxifene has a lower risk of endometrial cancer and thromboembolic events than tamoxifen, but it is not indicated for the treatment of established breast cancer.
• Non‑hormonal chemotherapy and targeted therapies: For ER+ breast cancer, particularly in advanced disease, CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) in combination with endocrine therapy have become standard of care. Chemotherapy is reserved for patients with high‑risk features or triple‑negative disease.
• Risk‑reducing mastectomy: In women at extremely high genetic risk (e.g., BRCA1/2 mutation carriers), bilateral prophylactic mastectomy is the most effective method of breast cancer risk reduction.
• Lifestyle modifications: For all women, a healthy diet, regular physical activity, weight management, and moderation of alcohol are important for general health and may contribute to breast cancer risk reduction.

Clinical Efficacy

The efficacy of tamoxifen in the adjuvant treatment of ER+ breast cancer has been demonstrated in numerous large, randomised controlled trials. The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta‑analysis, which included data from over 30,000 women, showed that 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by approximately 31% in women with ER+ disease, regardless of age, nodal status, or use of chemotherapy. The absolute risk reduction in 15‑year breast cancer mortality was 9–11%. Tamoxifen also reduced the risk of contralateral breast cancer by about 50%. For women with DCIS, tamoxifen reduced the risk of ipsilateral and contralateral breast cancer events. In the NSABP P‑1 (Breast Cancer Prevention Trial), tamoxifen 20 mg daily for 5 years reduced the risk of invasive breast cancer by 49% in women at high risk. The International Breast Cancer Intervention Study (IBIS‑I) and other prevention trials have confirmed these findings, and the protective effect persists for at least 5–10 years after stopping treatment. Tamoxifen is listed on the World Health Organization Model List of Essential Medicines and remains a cornerstone of endocrine therapy for premenopausal women and selected postmenopausal women, particularly when aromatase inhibitors are contraindicated or not tolerated. In Canada, tamoxifen is widely available, fully reimbursed by provincial formularies, and is recommended by the Canadian Cancer Society and the Canadian Task Force on Preventive Health Care for breast cancer risk reduction in eligible women.

Important:

Tamoxifen is a prescription medication that must be used under the supervision of a qualified healthcare professional, ideally an oncologist. It can cause life‑threatening adverse effects, including endometrial cancer, uterine sarcoma, venous thromboembolism (blood clots), and stroke. Women taking tamoxifen must have regular gynaecological check‑ups, and any abnormal vaginal bleeding must be investigated immediately. Do not become pregnant while taking tamoxifen; effective non‑hormonal contraception must be used. Tamoxifen should be discontinued at least 2–3 weeks before major surgery and during prolonged immobilisation. If you experience leg swelling, chest pain, shortness of breath, sudden severe headache, vision changes, or unexplained vaginal bleeding, stop taking tamoxifen and seek emergency medical attention. Do not take tamoxifen with strong CYP2D6 inhibitors (such as paroxetine or fluoxetine) without consulting your doctor, as these may reduce the drug’s effectiveness. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Tamoxifen - Shipping across Canada